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ABSTRACT The oncogenic transcription factor FoxM1 plays a vital role in cell cycle
progression, is activated in numerous human malignancies, and is linked to chromo-
some instability. We characterize here a cullin 4-based E3 ubiquitin ligase and its
substrate receptor, VprBP/DCAF1 (CRL4VprBP), which we show regulate FoxM1 ubiqui-
tylation and degradation. Paradoxically, we also found that the substrate receptor
VprBP is a potent FoxM1 activator. VprBP depletion reduces expression of FoxM1
target genes and impairs mitotic entry, whereas ectopic VprBP expression strongly
activates a FoxM1 transcriptional reporter. VprBP binding to CRL4 is reduced during
mitosis, and our data suggest that VprBP activation of FoxM1 is ligase independent.
This implies a nonproteolytic activation mechanism that is reminiscent of, yet dis-
tinct from, the ubiquitin-dependent transactivation of the oncoprotein Myc by other
E3s. Significantly, VprBP protein levels were upregulated in high-grade serous ovar-
ian patient tumors, where the FoxM1 signature is amplified. These data suggest that
FoxM1 abundance and activity are controlled by VprBP and highlight the functional
repurposing of E3 ligase substrate receptors independent of the ubiquitin system.
KEYWORDS cell cycle, cullin ring ligase, FoxM1, transcriptional regulation,
ubiquitination
Changes in gene expression combined with targeted protein degradation dynami-cally shape the protein landscape. Gene expression is coordinated by transcription
factors that specify genes for activation and cofactors that modulate transcription
factor activity or alter the local chromatin environment. Posttranslational modifications
(PTMs) play a crucial role in transcriptional dynamics. Phosphorylation, acetylation,
methylation, and ubiquitylation of histone proteins are well studied and contribute
significantly to gene expression dynamics (1). Similarly, posttranslational modification
of transcription factors plays an important role in regulating genome output.
FoxM1 is an oncogenic, cell cycle-regulated transcription factor that was discovered
as both a marker and a key mediator of cell proliferation (2–4). Subsequent work
clarified the importance of FoxM1 in proliferation through its role in cell cycle progres-
sion (reviewed in reference 5). FoxM1 controls the mitotic transcriptional program, and
its depletion significantly impairs normal mitotic entry and progression (6–9). In addi-
tion, FoxM1 and its transcriptional network have been associated with numerous
cancers (5, 10). Notably, FoxM1 is the key regulator of a proliferative gene expression
signature found in high-grade serous ovarian cancer (HGSOC), basal-like breast cancers,
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and uterine serous carcinomas (11–13). In HGSOC, the FoxM1 signature is upregulated
in nearly 90% of patient tumors (12).
FoxM1 activity peaks in G2/M phase, consistent with its role in dictating mitotic gene
expression, and several kinases have been implicated in its activation (6, 14–18). FoxM1
is repressed by an intramolecular interaction with its amino-terminal domain, and this
inhibition is relieved by cyclin-dependent kinase (CDK) phosphorylation (19). In addi-
tion, the cell cycle kinases MELK and PLK1 can activate FoxM1 (20–24).
In addition to phosphorylation, posttranslational addition of ubiquitin is utilized to
control gene expression. The oncogenic transcription factor c-Myc highlights the
complex role that ubiquitin plays in transcriptional regulation (25). Myc is targeted for
proteolysis by several E3 ubiquitin ligases, including a Skp1-, cullin 1-, F-box-containing
complex (SCF)-type cullin ring ligase (CRL) and the substrate receptor Skp2 (SCFSkp2)
(26, 27). Whereas protein ubiquitylation and degradation are most often considered
inactivating events, unexpectedly, Skp2 activates Myc-dependent transcription (26, 27).
Ubiquitylation-dependent activation of Myc is further borne out by studies using a
lysine-less version that cannot be ubiquitylated and is deficient in activating transcrip-
tion (28). The role of ubiquitylation in transcriptional activation builds on pioneering
studies on the VP16 transcription activation domain whose activation in yeast requires
an SCF ligase together with its substrate receptor Met30 (29). Furthermore, the ability
of the ubiquitin machinery to activate transcription is corroborated by regulation of the
human estrogen receptor (ER) and its coactivator, SRC-3/AIB1, whose degradation is
coupled to activation (29–32). Together, these studies highlight the complex role that
ubiquitin plays in transcriptional control.
The role of ubiquitin ligases in activating FoxM1 has not been studied. We recovered
FoxM1 in a global screen for substrates of the modular CRLs, which represent the
largest E3 ligase family in humans (33). CRL assembly is based on a common molecular
scaffold and relies on a cullin backbone that simultaneously engages substrates and E2
ubiquitin-conjugating enzymes. Cullin 4-based ligases (CRL4) use either of two highly
related cullin proteins, Cul4A or Cul4B, that bind to the triple--propeller protein DDB1.
Substrate receptor subunits bind directly to DDB1 and simultaneously recruit specific
proteins to the enzyme complex for ubiquitylation (schematic in Fig. 1A) (34). Human
Cul4A and Cul4B are highly similar (75% amino acid similarity); however, Cul4B has an
amino-terminal extension and localizes exclusively to the nucleus, whereas Cul4A is
both nuclear and cytoplasmic (35). Importantly, CRL4 function has been linked to
chromatin regulation, cell cycle, viral infection, and the DNA damage response (34).
More than 50 CRL4 substrate receptors, termed DCAFs or DWD proteins (DDB1- and
Cul4-associated factors; DDB1 binding WD40 proteins), have been identified (36–38).
VprBP/DCAF1 is a nucleus-localized CRL4 substrate receptor named for its ability to
bind the HIV accessory protein Vpr (and Vpx) following viral infection (39). Ectopic Vpr
expression in human cells triggers a G2 arrest that is dependent on CRL4VprBP (reviewed
in reference 40). Significantly, VprBP associates with chromatin only during the G2/M
phase of the cell cycle (41). Knockout of VprBP in mice causes embryonic death prior
to embryonic day 7.5 (E7.5), and conditional inactivation of VprBP in mouse cells or
depletion using RNA interference (RNAi) in human cells produces cell cycle defects (41).
Despite its importance in cell cycle control and development, CRL4VprBP has few known
substrates and it remains unclear how it contributes to cell cycle progression. Endog-
enous CRL4VprBP substrates include the methylcytosine dioxygenase Tet2 (42) and the
replication regulator Mcm10 (43). Other proteins are targeted for ubiquitylation only in
response to HIV infection and include the phosphohydrolase SamHD1 (44). VprBP has
been linked to the NF2 tumor suppressor and YAP-dependent transcription, suggesting
a role in transcriptional regulation and cancer (45). Here, we describe a role for VprBP
in controlling both the degradation and the activation of FoxM1.
RESULTS
FoxM1 stability is regulated by CRL4VprBP. Using a fluorescence-based genetic
reporter system termed global protein stability profiling (GPS), we previously searched
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for substrates of the Cul4-based cullin ring ligase (CRL4) (33). The GPS expression
system relies on a viral vector that expresses a bicistronic mRNA encoding both DsRed
and an enhanced green fluorescent protein-open reading frame (EGFP-ORF) fusion
protein. Using this system, we infer relative changes in the stability of EGFP-ORF fusions
by examining the ratio between EGFP and DsRed fluorescence using flow cytometry.
DsRed normalizes for expression of the reporter cassette on a single-cell basis. Using
this system, we screened a pooled library of 293T cells expressing more than 13,000
individual EGFP-ORF fusion proteins (one ORF per cell). A schematic overview of the
GPS screening system is depicted in Fig. S1 in the supplemental material and is
described in detail elsewhere (33, 46).
To identify proteins whose stability is controlled by CRL4, we turned off the ligase
by introducing a dominant negative construct targeting Cul4 and compared results
under this condition to those obtained with a negative-control vector (33). GPS library
cells from these two conditions were sorted into bins based on their EGFP/DsRed ratio
using fluorescence-activated cell sorting (FACS). Genomic DNA (gDNA) was isolated
from sorted cells in each bin, and ORFs were amplified from gDNA using PCR primers
FIG 1 FoxM1 is regulated by Cul4, DDB1, and VprBP. (A) Illustration of the CRL4 complex. DDB1 bridges
either Cul4A or Cul4B to substrate adaptor subunits termed DCAF or DWD proteins. Substrates are
ubiquitylated by E2 enzymes that are recruited to the cullin backbone by Rbx1 or Rbx2. (B) FoxM1 scored
in a GPS screen for CRL4 substrates. Three independent microarray probes were shifted in response to
dominant negative Cul4 treatment. (C) U2OS cells treated with MLN4924 for 4 h and analyzed by
immunoblotting. (D) U2OS cells were treated with siRNAs targeting FF (control), DDB1, Cul4A, or Cul4B and
analyzed by immunoblotting after 72 h. (E) U2OS cells stably expressing Myc-FoxM1 were treated with
siRNAs targeting firefly luciferase (FF), DDB1, Cul4A, Cul4B, or VprBP and analyzed by immunoblotting after
72 h. (F) U2OS and HeLa cells treated with siRNAs targeting FF or VprBP and analyzed by immunoblotting
after 72 h. (G) U2OS cells treated with siRNAs targeting FF or VprBP were synchronized in S phase using
thymidine. Cycloheximide was added 4 h after release into the cell cycle, and FoxM1 stability was analyzed
by immunoblotting.
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designed against the viral backbone. Amplified ORF DNA was labeled and hybridized to
custom-designed DNA microarrays containing multiple independent probes per gene.
Quantifying the distribution of probe signals across bins allows us to infer changes in
the stability of EGFP-ORFs (33). For example, a shift in the probe distribution to
higher-numbered bins suggests that cells expressing a particular EGFP-ORF showed an
increase in their EGFP/DsRed ratio, indicative of an increase in the stability of the
EGFP-ORF fusion protein.
Three of the four probes corresponding to FoxM1 showed a shifted distribution after
dominant negative Cul4 treatment, suggesting that EGFP-FoxM1 was stabilized by
CRL4 inactivation (Fig. 1B). These three probes showed a highly consistent distribution
across bins, suggesting that they accurately report the distribution of EGFP-FoxM1-
expressing cells and that FoxM1 stability is regulated by CRL4.
To validate endogenous FoxM1 as a CRL substrate, we treated cells with MLN4924,
a pharmacological small-molecule inhibitor that impairs CRL activation by interfering
with the neddylation cascade (47). FoxM1 abundance was increased after a 4-h
MLN4924 treatment in both 293T and U2OS cells (Fig. 1C; see also Fig. S2A in the
supplemental material). The slower-migrating, neddylated form of Cul4 was undetect-
able after MLN4924 treatment, showing that neddylation was impaired (Fig. S2A). We
next determined if FoxM1 is regulated by Cul4. We treated cells with small interfering
RNA (siRNA) targeting either Cul4A, Cul4B, or DDB1 or with control oligonucleotides
targeting firefly luciferase (FF). Seventy-two hours after transfection, cells were har-
vested for immunoblotting. Depletion of DDB1 and Cul4B led to a reproducible
increase in the abundance of endogenous FoxM1, whereas depletion of Cul4A had a
weaker and less consistent effect (Fig. 1D). Consistently, depletion of DDB1 and Cul4B
increases the abundance of Myc-FoxM1, which is stably expressed from a heterologous
promoter, and again, Cul4A had no effect (Fig. 1E; the underlining corresponds to the
antigen used for blotting, e.g., Myc-FoxM1). Taken together, these data suggest that
FoxM1 stability is regulated by CRL4.
The two best-studied CRL4 substrate receptors implicated in cell cycle control are
Cdt2 and VprBP. Cdt2 engages substrates through a degron embedded within a
PCNA-interacting peptide motif (PIP-box) (48). However, FoxM1 lacks a PIP-box. We
therefore depleted VprBP using siRNA and measured FoxM1 abundance by immuno-
blotting. Depletion of VprBP increased endogenous FoxM1, as well as the known
substrate Mcm10, in both HeLa and U2OS cells (Fig. 1F).
FoxM1 is degraded in G1 phase by the APC/CCdh1 ubiquitin ligase (49, 50). To
determine if VprBP regulates FoxM1 at other times during the cell cycle and to rule out
the possibility that differences in FoxM1 abundance were due to changes in cell cycle
progression, we treated U2OS cells with siRNA targeting VprBP and then synchronized
cells using thymidine in accordance with a previously established protocol (51). Cells
were harvested 0, 2, 4, and 6 h after release and analyzed by immunoblotting. FoxM1
was consistently increased in the VprBP-depleted cells (Fig. S2B), suggesting that VprBP
regulates FoxM1 degradation and that the increase in FoxM1 abundance is indepen-
dent of gross cell cycle changes. Two independent siRNA oligonucleotides targeting
VprBP produced a similar increase in FoxM1 levels in S-phase-synchronized cells (Fig.
S2C). Similarly, we synchronized HCT116 cells in early S phase, late S phase/G2, and
G2/M phase using thymidine, thymidine block and release, and nocodazole, respec-
tively. FoxM1 was increased in synchronized, VprBP-depleted cells, indicating that
VprBP controls FoxM1 abundance, independent of its effect on the cell cycle (Fig. S2D).
Next, we measured FoxM1 stability/half-life in control and VprBP-depleted cells that
were synchronized in S phase, 2 h after thymidine release. VprBP depletion increased
FoxM1 stability after treatment with the protein synthesis inhibitor cycloheximide (CHX)
(Fig. 1G). Interestingly, in both control and VprBP-depleted cells, FoxM1 levels tran-
siently increased after the addition of CHX. This is a highly reproducible result observed
across several experiments. The acute increase in FoxM1 is evident in otherwise-
untreated cells after the addition of CHX (Fig. S2E). While the mechanism underlying
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this phenomenon remains unclear, it has long been appreciated that some proteins can
increase following treatment with CHX (52).
FoxM1 interaction and ubiquitylation by VprBP. We next determined if VprBP
binds to FoxM1 in HEK-293T cells transiently transfected with Myc-FoxM1 and hemag-
glutinin (HA)-VprBP to examine the possibility that FoxM1 is a direct CRL4VprBP sub-
strate. Cells were treated with the proteasome inhibitor MG132 for 4 h prior to lysis and
coimmunoprecipitation (co-IP) to promote the interaction between E3 ligase and
substrate (53, 54). Following anti-HA-VprBP IP, we detected an interaction with FoxM1,
and this interaction was enhanced by treatment with MG132 (Fig. 2A; see also Fig. S3A
in the supplemental material). The interaction was also detectable when Myc-FoxM1
was immunoprecipitated (Fig. S3C). In addition, we precipitated endogenous FoxM1
from HEK-293T cell lysates and detected endogenous VprBP (Fig. 2B). Finally, we
determined if FoxM1 and VprBP can directly interact. We immobilized bacterially
purified 6His-tagged FoxM1 (FoxM1-6His) on nickel-agarose beads and mixed them
with purified, [35S]methionine-labeled VprBP produced in vitro using purified transcrip-
tion and translation machinery. VprBP bound to beads that had immobilized FoxM1-
6His but was observed only in the flowthrough of control beads, strongly suggestive of
a direct interaction (Fig. 2C).
To determine if VprBP can regulate FoxM1 ubiquitylation, we ectopically expressed
6His-ubiquitin in 293T cells with and without HA-VprBP. Cells were treated with MG132
prior to lysis in strong denaturing buffer (6 M guanidine–HCl), and 6His-ubiquitin
conjugates were isolated on nickel-agarose. VprBP expression enhanced the ubiquity-
lation of endogenous FoxM1, measured by immunoblotting for FoxM1 (Fig. 2D).
Likewise, VprBP significantly increased the ubiquitylation of ectopically expressed
Myc-FoxM1 (Fig. 2E). Therefore, VprBP regulates the abundance, stability, and ubiqui-
tylation of FoxM1.
To identify the domain in FoxM1 that interacts with VprBP, we synthesized a series
of constructs encoding 160-amino-acid (aa) fragments of the FoxM1 protein spanning
the length of its largest known open reading frame. We tested their ability to interact
by expressing full-length HA-VprBP and Myc-FoxM1 fragments in HEK-293T cells and
analyzing precipitates after anti-HA IP. A fragment of FoxM1 spanning amino acids 321
to 480 (FoxM1321–480) interacted most strongly with VprBP (Fig. S3B). The same
Myc-FoxM1321–480 fragment bound to VprBP when Myc was precipitated (Fig. S3C). We
conclude that the interaction between VprBP and FoxM1 is dependent on the region
of FoxM1 spanning amino acids 321 to 480.
To identify a degron sequence motif in FoxM1, we examined molecular and struc-
tural data of a known VprBP substrate. SamHD1 is targeted by CRL4VprBP after HIV
infection, and a ternary complex between VprBP, SamHD1, and the viral accessory
protein Vpx has been crystallized (Fig. 2F) (55). Importantly, the amino acids in SamHD1
that mediate binding to VprBP and degradation have been mapped (55, 56). A segment
between amino acids 615 and 625 in SamHD1 contributes significantly to VprBP
binding, and several residues in this region are critical for its degradation (55, 56). We
looked for matching sequences in FoxM1 between residues 321 and 480 and identified
a region of similarity between residues 414 and 422 (Fig. 2F, bottom panel). We
synthesized three mutant versions of the same region of aa 321 to 480, making amino
acid substitutions that correspond to residues that we predicted would affect recog-
nition by VprBP. These substitutions in FoxM1 included changes of RV to AA (aa 416
and 417), RI to AA (aa 418 and 419), and K to A (aa 422). We tested the ability of each
version of the fragment to bind HA-VprBP by co-IP following treatment with protea-
some inhibitors to normalize protein levels across IPs. We found that alanine substitu-
tions at residues 418 and 419 (RI to AA) and 422 (K to A) impaired binding to VprBP (Fig.
2G). Notably, K622 in SamHD1, corresponding to K422 in FoxM1, directly contacts
VprBP in the crystal structure and is required for SamHD1 degradation (55).
We next tested the stability of these fragments by CHX chase. Significantly, frag-
ments that showed reduced binding also had higher basal expression (note that these
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experiments were not done with proteasome inhibitors, in contrast to those whose
results are shown in Fig. 2D) and increased stability relative to the wild-type (WT)
fragment when expressed in 293T cells (Fig. 2H). We observed a similar increase in the
stability of full-length FoxM1 when amino acids in the putative degron motif were
changed (RVRIAPK to AAAAAPA; the half-life increased from 1.0 to 1.5 h). More-minor
changes, specifically, K422A, similarly extended the half-life (Fig. S2F and G). These data
are suggestive that this motif sequence, i.e., R-I/V-X-X-(X)-K, represents a putative VprBP
degron. Similar sequences are found in established substrates Tet2 and Mcm10 (Fig. 2F)
(42, 43).
FIG 2 VprBP binds and ubiquitylates FoxM1 in vivo. (A) HA-VprBP and Myc-FoxM1 were transiently expressed in
293T cells. VprBP was recovered on anti-HA-agarose and analyzed by immunoblotting. Cells were treated with
MG132 prior to lysis. (B) Endogenous FoxM1 was precipitated from a 293T cells extract and analyzed by
immunoblotting. (C) Bacterially purified FoxM1-6His was incubated with in vitro-produced, [35S]methionine-labeled
VprBP. Flowthrough and eluates after pulldown were analyzed by autoradiography. (D and E) 6His-ubiquitin was
transiently expressed in 293T cells with and without HA-VprBP. 6His-ubiquitin was recovered after lysis under
strong denaturing conditions and analyzed by immunoblotting. Analysis of either endogenous (D) or exogenously
expressed (E) Myc-FoxM1 was done by immunoblotting. (F) Crystal structure from Schwefel et al. (55) depicting the
interaction between VprBP and SamHD1. Alignment of similar residues between SamHD1, FoxM1, and two other
VprBP substrates (Tet2 and Mcm10) is shown below. (G) Amino acid substitutions were made in a FoxM1 fragment
(aa 321 to 480) corresponding to the residues found in the VprBP-SamHD1 interface. Binding was analyzed as
described for panel A between Myc-FoxM1321–480 and HA-VprBP. (H) The stability of Myc-FoxM1321–480 fragments
that were impaired in their binding to VprBP was analyzed by CHX chase.
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VprBP is a FoxM1 activator. To address the contribution of VprBP to FoxM1
activity, we utilized a well-characterized FoxM1 luciferase reporter construct (6DB)
(23). We measured reporter activity following transient expression of FoxM1 and VprBP
in HEK-293T cells. Expression of FoxM1 increased reporter activity as expected (Fig. 3A).
Remarkably, we also observed a strong, dose-dependent increase in reporter activity in
response to VprBP when coexpressed with FoxM1 (Fig. 3A). We compared the ability of
VprBP to activate FoxM1 to that of the known coactivator MELK (24). VprBP activated
the reporter to a greater extent than MELK when transfected in equal amounts (Fig. 3B).
Furthermore, VprBP activates the 6DB reporter in the absence of ectopically ex-
pressed FoxM1 (Fig. 3B). We also measured the effect of VprBP on an unrelated
luciferase reporter controlled by the oxidative stress response transcription factor Nrf2.
FoxM1 and VprBP expression did not affect the Nrf2 luciferase reporter, whereas strong
activation was achieved by Nrf2 expression (see Fig. S4A in the supplemental material).
We next expressed the 6DB reporter with increasing amounts of VprBP and
analyzed luciferase activity, cell cycle dynamics, and protein abundance all in the same
experiment (Fig. 3C). VprBP activated reporter activity at both 24 and 48 h posttrans-
fection in a dose-dependent manner (Fig. 3C.1). Importantly, the abundance of FoxM1
FIG 3 VprBP activates the FoxM1 6DB transcriptional reporter. (A) FoxM1 and VprBP were expressed in
293T cells in combination with the 6DB reporter. Luciferase activity was measured 48 h after trans-
fection (error bars show standard deviations for technical triplicates). (B) Combinations of MELK, FoxM1,
and VprBP were expressed in 293T cells with the 6DB reporter. Luciferase activity was measured 48 h
after transfection (error bars show standard deviations for technical triplicates). (C.1 to C.3) High and low
concentrations of VprBP were expressed in 293T cells with the 6DB reporter. At 24 and 48 h after
transfection, identical populations of cells were measured for luciferase activity (C.1) and harvested and
split for analysis by immunoblotting (C.2) and cell cycle analysis (C.3). Luciferase activity was measured
(error bars show standard deviations for technical triplicates).
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remained unchanged at both time points and concentrations of VprBP (Fig. 3C.2). This
demonstrates that the change in reporter activity is not due to changes in the overall
level of FoxM1. It also suggests that VprBP does not activate FoxM1 by triggering its
degradation, as is the case for Myc activation by Skp2 (26, 27). We examined the cell
cycle using propidium iodide staining and analysis by flow cytometry and found no
significant changes at either time point relative to controls (Fig. 3C.3). We therefore
conclude that VprBP activates FoxM1 and that activation is independent of FoxM1
abundance and is not due to gross changes in cell cycle dynamics.
To directly interrogate the consequence of VprBP depletion on FoxM1 activity, we
measured the transcript levels of FoxM1 target genes in synchronized U2OS cells (to
alleviate cell cycle effects) that were depleted of VprBP. First, U2OS cells were synchro-
nized in G2/M following an 8-h release from thymidine block. The mRNA from control
and VprBP-depleted cells was isolated, and FoxM1 target gene expression was mea-
sured using quantitative reverse transcription-PCR (RT-qPCR). The expression of several
FoxM1 target genes was reduced in VprBP-depleted cells, including CDC25B, CCNB1,
PLK1, and CENPF (Fig. 4A). The expression of VprBP was reduced by siRNA treatment as
expected; however, the level of FoxM1 mRNA was unchanged. We performed a similar
experiment by treating the cells with siRNA targeting FF, FoxM1, and VprBP and then
blocking cells in mitosis with nocodazole. Mitotic cells were specifically isolated by
shake-off, and we found that the expression of CDC25B, PLK1, and CCNB1 was reduced
to a similar extent in both FoxM1 and VprBP-depleted cells relative to controls (Fig.
S4B). We therefore conclude that VprBP activates the transcription of FoxM1 target
genes during the G2/M phase of the cell cycle.
FoxM1 has been implicated in mitotic entry and progression (6, 7). We examined the
role of VprBP in cell cycle progression since its depletion reduces the expression of
several FoxM1 target genes. U2OS cells were treated with either control or VprBP
siRNAs and after 72 h were fixed and processed for phospho-histone H3 (P-H3)
immunostaining to mark mitotic cells. Imaging was performed, and the percentage of
P-H3-positive cells was determined. Eight percent of cells were in mitosis in control
depleted populations (Fig. 4B). Depletion with two independent VprBP siRNAs signifi-
cantly reduced the percentage of P-H3-positive mitotic cells, to 2.8% and 0.5% (Fig. 4B).
FIG 4 VprBP depletion reduces FoxM1 target gene expression and the number of mitotic cells. (A) U2OS cells treated with
siRNAs targeting FF or VprBP were synchronized in G2/M using a thymidine block and release. The expression of FoxM1
target genes was analyzed using RT-qPCR (error bars show standard deviations for technical triplicates). (B) U2OS cells
treated with siRNAs targeting FF or VprBP were fixed and immunostained for phospho-histone H3 Ser10. DNA was
counterstained with Hoechst stain. Images were captured using an automated imaging system, and the percentage of
P-H3S10-positive cells was calculated from six wide-field images captured on an automated system. Representative images
are shown.
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Thus, VprBP depletion blocks the accumulation of mitotic cell cycle genes and prevents
M-phase entry, consistent with a role for VprBP in activating FoxM1.
We determined if VprBP localizes to the promoters of FoxM1 target genes, since it
binds FoxM1 and regulates FoxM1 target gene expression. U2OS cells were synchro-
nized in G2/M phase and processed for chromatin immunoprecipitation (ChIP). Immu-
noprecipitation was performed in parallel with antibodies to control IgG, FoxM1, and
VprBP. We detected an enrichment of both VprBP and FoxM1 at the promoters of
previously characterized FoxM1 promoters, including PTMS, BRCA2, and FZR1 (17).
VprBP localized to a lesser extent to the FoxM1 targets CENPF and CDK1 (Fig. 5A). Thus,
FoxM1 and VprBP colocalize to FoxM1 target gene promoters.
Myc and ER are activated by ubiquitylation via their respective ligases (26, 27, 57).
We sought to gain similar mechanistic insight into the regulation of FoxM1 by VprBP.
We determined if two independent versions of VprBP that are impaired in binding
FIG 5 VprBP associates with FoxM1 promoters and activates independently from Cul4. (A) U2OS cells
were synchronized in G2/M phase and fixed for ChIP analysis with control IgG, FoxM1, and VprBP
antibodies. VprBP associated with the promoters of some FoxM1 target genes. (B) VprBPWT and mutant
versions that are impaired in binding DDB1 (RARA and N909) were expressed in 293T cells in combination
with the 6DB reporter. Luciferase activity was measured 48 h after transfection (error bars show
standard deviations for technical triplicates). (C) HA-VprBP was transiently expressed in 293T cells that
were subsequently treated with nocodazole or vehicle control (DMSO). VprBP was recovered on
HA-agarose following lysis and analyzed by immunoblotting. (D) HA-VprBP and Myc-FoxM1 were
transiently expressed in 293T cells that were subsequently treated with nocodazole or vehicle control
(DMSO). VprBP was recovered on HA-agarose following lysis and analyzed by immunoblotting.
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DDB1 (N909 and RARA) are able to increase FoxM1 reporter activity (42). The 6DB
reporter activity was increased using an amino-terminal fragment of VprBP (N909) that
cannot bind to the DDB1/Cul4 complex (Fig. 5B). Similar results were obtained with a
mutant version of VprBP (RARA) that is also impaired in DDB1/Cul4 binding (Fig. 5B)
(42). The response of 6DB to VprBPWT, VprBPN909, and VprBPRARA is dose dependent
(Fig. S4C). We conclude that VprBP activation of FoxM1 is independent of the CRL4
complex. These data also suggest that FoxM1 activation by VprBP is not due to a
change in the abundance or stability of a secondary, unknown CRL4VprBP substrate.
We next asked if VprBP is still bound to Cul4B and DDB1 at a time in the cell cycle
when FoxM1 is active. We introduced HA-VprBP into 293T cells that were then treated
with either nocodazole or dimethyl sulfoxide (DMSO). Cells were lysed, and HA-VprBP
immunoprecipitates were analyzed by immunoblotting. We found that the association
of HA-VprBP with endogenous Cul4B, and to a lesser extent DDB1, was reduced in
mitotic cells (Fig. 5C, lanes 6 versus 8). However, there was no change in the interaction
between VprBP and FoxM1 in mitosis (Fig. 5C and D). Thus, VprBP association with the
CRL4 complex is cell cycle regulated, and its partial dissociation coincides with the time
at which FoxM1 is activated.
VprBP protein is upregulated in high-grade serous ovarian tumors. The FoxM1
gene expression signature is upregulated in 90% of high-grade serous ovarian
cancers (HGSOC) (12). However, the FoxM1 mRNA is overexpressed in only 12% of
tumors. To analyze the expression of VprBP in HGSOC tumors, we obtained surgically
resected ovaries from HGSOC patients that had been histologically confirmed as serous
ovarian cancer. As controls, we examined ovaries from women who underwent oo-
phorectomy for reasons other than gynecological malignancy. FoxM1 levels were not
elevated in HGSOC tumors relative to controls. Remarkably, VprBP protein was upregu-
lated in seven of nine HGSOC tumors tested relative to control ovaries, where its levels
were low or undetectable (Fig. 6A). Further, the well-established FoxM1 target cyclin B
was expressed in six of the seven tumors in which VprBP was increased. VPRBP is not
overexpressed at the mRNA level in HGSOC based on genomic analysis, suggesting that
posttranscriptional mechanisms account for its overexpression (12).
FIG 6 Implication in cell cycle control and malignancy. (A) Ovaries resected from patients with HGSOC
were compared to normal ovaries by immunoblotting. (The dotted line indicates the splicing together
of samples run on the same gel.) (B) Our data suggest that VprBP contributes to the degradation and
activation of FoxM1. VprBP binds to the CRL4 ligase complex and targets FoxM1 for degradation during
S phase. During G2/M phases, when FoxM1 activity peaks, VprBP disengages from CRL4 and acts as a
coactivator. FoxM1 is ubiquitylated and degraded by APC/CCdh1 during G1 phase.
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DISCUSSION
Ubiquitylation has long been implicated as a key regulator of transcription and
chromatin regulation in human cells. Ubiquitin was identified due to its conjugation to
the core histone H2A and only later was identified by Hershko and colleagues as part
of the intracellular protein degradation system (58). The yeast -2 transcriptional
repressor was one of the first identified in vivo targets of ubiquitin-dependent protein
degradation (59). Ubiquitin has been best described for its role in inactivating target
proteins through proteolysis. However, the emergence of complex ubiquitin chains of
various topologies and the identification of their roles in various aspects of cellular
physiology, besides protein degradation, illustrate the complex and sometimes para-
doxical role that the ubiquitin machinery can play in signal transduction.
These multiple functions are evident in the role of ubiquitin signaling in transcrip-
tional regulation. Interestingly, transcription factors and transcriptional coactivators can
be activated by the ubiquitin machinery. For example, the transcriptional activation
domain (TAD) of VP16 is activated in yeast by the SCF substrate receptor F-box protein,
Met30 (29). Moreover, fusion of ubiquitin directly to VP16 restores its activity in the
absence of Met30 without affecting VP16-TAD stability, providing an example of
ubiquitin-dependent, degradation-independent transcriptional activation (29). There
are also well-established examples of ubiquitin- and proteasome-dependent transcrip-
tional activation in human cells. First is the Myc transcription factor. Myc degradation
is controlled by the SCF (Skp2) E3 ubiquitin ligase, and Skp2 also promotes Myc
transcriptional activation (26, 27). Consistently, a lysine-less version of Myc, which
cannot be ubiquitylated and degraded with normal kinetics, still binds to the coacti-
vator Max and localizes to target gene promoters but is unable to fully activate gene
expression (28). Similarly, ER is ubiquitylated and degraded in response to ligand
(estrogen), and this is required for its full activation (30).
Here we show a FoxM1 activation mechanism that is ubiquitin and degradation
independent yet involves a component of the ubiquitin system that can also regulate
its destruction. We found that FoxM1 is a substrate of the CRL4VprBP E3 ubiquitin ligase.
Analogous to Myc activation by Skp2, we discovered that VprBP potently activates
FoxM1. However, the FoxM1 reporter was activated by two independent versions of
VprBP that are impaired in binding to CRL4. Moreover, we demonstrate biochemically
that VprBP is partially dissociated from the CRL4 complex at the time during the cell
cycle when FoxM1 activity peaks. Together, these data suggest that FoxM1 activation
by VprBP is ubiquitin and degradation independent. The ability of VprBP to activate
FoxM1 independent of CRL4 binding provides a clear demonstration of E3 ligase
substrate receptor repurposing. Moreover, it suggests the possibility that the activity of
other CRL substrate receptors can be context dependent and dynamically altered by
controlling their association with ubiquitin machinery.
We hypothesize that VprBP acts as a rheostat to control FoxM1 degradation and
activation (Fig. 6). FoxM1 abundance is tightly controlled throughout the cell cycle by
ubiquitylation. By tempering FoxM1 accumulation, VprBP could impair its activation.
Late in the cell cycle, before mitosis, FoxM1 activity increases, contributing significantly
to the expression of genes involved in mitotic entry and progression (9). At this time,
the partial dissociation of VprBP from DDB1 and Cul4 (Fig. 5) would enhance its ability
to activate FoxM1 (14). Consistent with this prediction, VprBP partially dissociates from
CRL4 in mitosis and a mutant version of VprBP that is impaired for DDB1 binding can
still activate FoxM1. Importantly, since VprBP depletion increases FoxM1 protein levels
in mitotic cells, it is unlikely that VprBP acts through a switchlike mechanism, whereby
it is either targeting FoxM1 for degradation or promoting its activation. In a rheostat
model, VprBP could tune the output of FoxM1 by controlling both its activation and its
degradation, with the relative role of each in a given cell determined by the extent of
CRL4(VprBP) disassembly. It is interesting that VprBP is unique among CRL4 substrate
receptors in that it is likely stoichiometrically bound to CRL4 (41, 60). In addition, VprBP
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association with chromatin is tightly cell cycle regulated and occurs only at the time
when FoxM1 is activated (G2/M).
The mechanism by which VprBP dissociates from CRL4 remains unknown. We
predict that posttranslational modification of VprBP could alter its chromatin associa-
tion and/or binding to DDB1/Cul4. Alternatively, modification of DDB1 or Cul4 could
regulate their association with VprBP. Modifications that affect FoxM1-VprBP binding
cannot be ruled out, although they did not change in mitosis in our experiments. It is
interesting that Chk2 phosphorylates FoxM1 in the same region as the one that we
mapped as being important for VprBP binding (61) and Chk2 has been linked to mitotic
progression (62). Dissecting the signaling pathways that control the relationship and
interactions between VprBP, CRL4, and FoxM1 is an important area of future study.
FoxM1 is activated in a variety of human malignancies. Specifically, its transcriptional
signature is upregulated in HGSOC, serous uterine cancer, and basal-like breast cancer
(11–13). However, it is mechanistically unclear how FoxM1 is activated in each of these
disease subtypes. Defects in ubiquitin signaling have been linked to changes in
transcription factor stability in malignancies. This is illustrated by the regulation of p53
by Mdm2, as well as mutations FbxW7 that affect Myc. Unlike these two prominent
examples, VprBP is neither significantly mutated nor transcriptionally altered in cancers
in which the FoxM1 signature is upregulated. However, we show that VprBP is over-
expressed at the protein level in HGSOC patient tumors. This suggests that VprBP
might, in part, contribute to the FoxM1 expression signature observed in these cancers.
It is important to note that cyclin B gene and other G2/M genes can be controlled by
multiple factors and FoxM1 itself is controlled by myriad mechanisms. Since VprBP is
not overexpressed at the mRNA level based on transcriptomic analysis, it is presumably
due to regulation of either its translation or its degradation. Cross talk between cell
cycle E3 ligases is an emerging theme in cell cycle control (63), and perhaps VprBP
stability is controlled by a second ubiquitin ligase.
MATERIALS AND METHODS
Immunoblot analysis. Cell extracts were prepared by lysis in ice-cold NETN buffer [20 mM Tris [pH
8.0], 100 mM NaCl, 0.5 mM EDTA, 0.5% NP-40, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF),
10 g/ml leupeptin, 2 g/ml aprotonin, 2 g/ml pepstatin A]. Cells were lysed on ice for 15 min and then
centrifuged at 14,000 rpm for 15 min at 4°C. Supernatant was collected, and protein concentrations were
determined by the Bradford assay.
Tumor specimens were sampled from patients undergoing surgery for HGSOC at the University of
North Carolina at Chapel Hill. The protocol was reviewed and exemption granted by the Institutional
Review Board at the university. To extract protein from tissues, normal ovarian tissues and ovarian tumors
were homogenized in ice-cold tissue homogenizing buffer (10 mM HEPES [pH 7.4], 50 mM
-glycerophosphate, 1% Triton X-100, 10% glycerol, 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol [DTT],
10 mM NaF, 1 mM Na3VO4, 10 g/ml leupeptin, 2 g/ml aprotonin, 2 g/ml pepstatin A, and 1 mM
AEBSF) using TissueLyser II (Qiagen). The homogenates were placed on ice for 15 min and then
centrifuged at 14,000 rpm for 15 min at 4°C. Supernatant was collected, and protein concentrations were
determined by the Bradford assay.
For immunoblotting, samples were heated for 5 min at 95°C before electrophoresis. Samples were
analyzed by SDS-PAGE using either homemade or Bio-Rad TGX gels, which were subsequently trans-
ferred onto nitrocellulose membranes (Bio-Rad). Membranes were blocked with 5% bovine serum
albumin (BSA). Antibodies were incubated overnight, and signals were detected using Pierce ECL
(Thermo Scientific). The primary antibodies used for immunoblot analysis, their sources, and the
concentrations used are described in detail in the supplemental information. Secondary antibodies
conjugated to horseradish peroxidase (HRP) were purchased from Jackson ImmunoResearch Labo-
ratories.
Immunoprecipitation. Briefly, soluble protein extracts were prepared from HEK-293T cells tran-
siently transfected with HA-VprBP and Myc-FoxM1 (wild type or mutants). Cells were lysed in NETN as
described above. Precipitation was performed by rotating 50 l of EZview Red anti-HA affinity gel or
EZview Red anti-c-Myc affinity gel (Sigma) with 2 mg of soluble, clarified lysate overnight at 4°C. The
affinity resin was recovered by centrifugation at 1,000  g for 1 min and washed 3 times with ice-cold
lysis buffer. Precipitates were eluted in SDS-PAGE buffer and analyzed by immunoblotting.
RT-qPCR. Total RNA was isolated with an RNeasy Plus minikit (Qiagen) and then reverse transcribed
with a SuperScript III first-strand synthesis system (Invitrogen). The resulting cDNA was used for
quantitative PCR with iTaq Universal SYBR green supermix (Bio-Rad). Data were normalized to GAPDH
(glyceraldehyde-3-phosphate dehydrogenase). Real-time PCR and data collection were done with a
QuantStudio 6 Flex real-time PCR system and software (Applied Biosystems). All of the primer sequences
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used for RT-qPCR analysis, ChIP, and site-directed mutagenesis are described in the supplemental
information.
Luciferase reporter assays. The FoxM1 6DB luciferase reporter was a kind gift from Michael
Whitfield (Dartmouth University). HEK-293T cells grown on 12-well plates were transiently transfected
with 6  DB reporter in combination with different constructs (FoxM1, MELK, and VprBP) using PolyJet
Plus transfection reagent (SignaGen Laboratories). The MELK expression vector was a kind gift from Lee
Graves (University of North Carolina). The Nrf2 expression vector and Nrf2 luciferase reporter were gifts
from Ben Major (University of North Carolina). VprBP expression vectors were a kind gift from Yue Xiong
(University of North Carolina). Cells were routinely collected at 48 h posttransfection. Luciferase activity
was measured using the luciferase reporter assay system (Promega). Experiments were performed in
three technical replicates each. Statistical differences were determined using Student’s t test.
Flow cytometry. For cell cycle profiling, trypsinized cells were washed with phosphate-buffered
saline (PBS), fixed in cold 70% ethanol, and stored overnight at 20°C. DNA was stained for 30 min in
25 g/ml propidium iodide and 100 g/ml RNase. Samples were analyzed using a CyAn flow cytometer
(Beckman Coulter) and FlowJo software.
In vivo ubiquitination assay. HEK-293T cells were cotransfected with 6His-ubiquitin and HA-VprBP,
with or without Myc-FoxM1. Forty-eight hours after transfection, cells were lysed in denaturing buffer,
mixed, and sonicated. Samples were incubated with equilibrated HisPur Ni-NTA Resin (ThermoFisher)
overnight at 4°C on a rotator. After repeated washing, the resin was eluted with SDS-PAGE sample buffer.
Detailed experimental procedures describing the wash and lysis buffers are described in reference 64.
Expression and binding assay for VprBP and FoxM1. VprBP was expressed from pcDNA3 using the
PURExpress system supplemented with [35S]methionine according to the manufacturer protocol. Full-
length FoxM1c (aa 1 to 763) was subcloned into pET-28b, producing a C-terminally 6His-tagged clone,
and expressed in Escherichia coli BL21(DE3) cells. Protein expression was induced with isopropyl--D-
thiogalactopyranoside (IPTG; 250 M) at 17°C for 18 h. The pellet was sonicated in 40 ml of lysis buffer
[20 mM KH2PO4 (pH 7.5), 500 mM NaCl, 10 mM imidazole, 1 mM Tris(2-carboxyethyl)phosphine (TCEP),
10% glycerol, 2 mM phenylmethylsulfonyl fluoride (PMSF), 1 protease tablet, 5 mM MgCl2, 40 units of
DNase I]. Lysis supernatant was loaded on a 5-ml HisTrap HP column, washed with buffer A (20 mM
KH2PO4 [pH 7.5], 500 mM NaCl, 10 mM imidazole, 1 mM TCEP, 10% glycerol), and eluted with buffer B
(20 mM KH2PO4 [pH 7.5], 500 mM NaCl, 500 mM imidazole, 1 mM TCEP, 10% glycerol). Protein fractions
were pooled and desalted with a 200-ml HiPrep 26/10 column into buffer C (20 mM KH2PO4 [pH 7.5], 200
mM NaCl, 10 mM imidazole, 1 mM TCEP).
Nickel-nitrilotriacetic acid (Ni-NTA) resin was prepared with wash buffer (20 mM KH2PO4 [pH 7.5], 200
mM NaCl, 10 mM imidazole, 1 mM TCEP, 0.002% Tween 20) and loaded with FoxM1c-6His. The column
was washed with 3 column volumes of wash buffer, and purified VprBP was added to the resin for 1 h
at 4°C. The resin was washed and eluted (using 20 mM KH2PO4 [pH 7.5], 200 mM NaCl, 500 mM imidazole,
1 mM TCEP, 0.002% Tween 20) at 75°C, and samples were visualized by autoradiography.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/MCB
.00609-16.
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